Status:
UNKNOWN
Role of Alprazolam in the Management of Acute Coronary Syndrome
Lead Sponsor:
Sohaib Ashraf
Conditions:
Acute Coronary Syndrome
Myocardial Infarction
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
PHASE2
Brief Summary
Cardiovascular disease has always been one of the most concerning ailments of all times considering mortality. On one end due to the emergence of pharmaceutical technology, there is a reduction in mor...
Detailed Description
World has studied the increased prevalence of anxiety as a concomitant factor in ACS patients causing detrimental effects on cardiovascular outcomes being anxiety as one of the first responses to ches...
Eligibility Criteria
Inclusion
- Systolic BP\>100mm Hg Age between 18-80 years Sinus Rhythm
Exclusion
- Cardiogenic Shock / Hypotension
- Known Asthma/COPD
- Bradycardia (HR \< 60)
- Already on Beta blockers/ Anxiolytics
- Sick sinus syndrome
- Second or third-degree heart block (in the absence of pacemaker)
- Decompensated heart failure
- With documented hypersensitivity to the drug or components
- Valvular Heart Diseases
- Congenital Heart Diseases
- Status post CABG
- Any co-morbidities except Diabetes Mellitus and Hypertension
Key Trial Info
Start Date :
December 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 20 2022
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT04715269
Start Date
December 25 2020
End Date
February 20 2022
Last Update
January 20 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shaikh Zayed Post-Graduate Medical Institute
Lahore, Pakistan, 54600